Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 9:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 1,981 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 0.9% Sodium Chloride (NaCl) Clear all
Completed Phase 2 Interventional Results available

The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose

NCT04977479
View directory record Official record
Conditions
Systemic Allergic Reaction
Interventions
Pfizer-BioNTech COVID-19 Vaccine (Comirnaty), Placebo, Pfizer-BioNTech COVID-19 Vaccine, Bivalent
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years to 69 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Not applicable Interventional

Topical and Oral Regimen for Skin Health

NCT04872946
View directory record Official record
Conditions
Skin Abnormalities
Interventions
Tea, Serum, Moisturizer
Dietary Supplement · Other
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

IVIG-eye Drops Treatment for Dry Eye Disease

NCT03992482
View directory record Official record
Conditions
Dry Eye
Interventions
Intravenous Immune Globulin (IVIG), Placebo
Drug
Lead sponsor
Sandeep Jain, MD
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 10, 2020 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 3 Interventional Results available

Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)

NCT02112656
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
ThermoDox, Dummy infusion
Drug
Lead sponsor
Imunon
Industry
Eligibility
18 Years and older
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 2 Interventional Results available

Stellate Ganglion Block (SGB) For Women for Breast Cancer

NCT02513329
View directory record Official record
Conditions
Hot Flushes, Hot Flashes
Interventions
Bupivicaine, Saline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 70 Years · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 17, 2026, 9:04 AM EDT
Recruiting Phase 3 Interventional

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation

NCT06959095
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Depemokimab, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
981 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
42
States / cities
Bakersfield, California • Modesto, California • Newport Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 1 Interventional

Inhaled Bicarbonate Therapy in Cystic Fibrosis

NCT00177645
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
sodium bicarbonate
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)

NCT00996437
View directory record Official record
Conditions
Vitreous Hemorrhage, Proliferative Diabetic Retinopathy
Interventions
Ranibizumab, Saline
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
67
States / cities
Phoenix, Arizona • Irvine, California • Loma Linda, California + 58 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Trans Sodium Crocetinate (TSC) in Enhancing Tissue Oxygen Levels in Healthy Volunteers

NCT04808622
View directory record Official record
Conditions
Healthy Subjects
Interventions
Trans-Sodium Crocetinate, Placebo
Drug
Lead sponsor
Diffusion Pharmaceuticals Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Oct 17, 2026, 9:04 AM EDT
Recruiting Phase 1 Interventional

HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors

NCT05861895
View directory record Official record
Conditions
Solid Tumors, Adult
Interventions
HF158K1 / 1.4 g lipid dose, HF158K1 / 2.2 g lipid dose, HF158K1 / 2.9 g lipid dose
Drug
Lead sponsor
HighField Biopharmaceuticals Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 2 Interventional

Determination of the Optimum Delivery Route for Botulinum Toxin A in Patients With Epiphora

NCT01282541
View directory record Official record
Conditions
Epiphora
Interventions
Botulinum Toxin Type A
Drug
Lead sponsor
Merbs, Shannath, M.D., Ph.D.
Individual
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2012 · Synced Oct 17, 2026, 9:04 AM EDT
Terminated Phase 1 Interventional

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

NCT03432741
View directory record Official record
Conditions
Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Breast Carcinoma, Refractory Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Nodal Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Belinostat, Carfilzomib, Copanlisib Hydrochloride, Daratumumab, Fludeoxyglucose F-18, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Nivolumab, Obinutuzumab, Pembrolizumab, Positron Emission Tomography, Rituximab, Romidepsin, Saline, Trastuzumab
Drug · Biological · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 26, 2025 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 2 Interventional Results available

Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

NCT00722553
View directory record Official record
Conditions
Carcinoma, Transitional Cell, Bladder Cancer, Bladder Neoplasm
Interventions
Pralatrexate Injection, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Tucson, Arizona • Atlanta, Georgia • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 17, 2026, 9:04 AM EDT
Recruiting Phase 2 Interventional

RE104 Safety and Efficacy Study in Generalized Anxiety Disorder

NCT07489651
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
RE104 for Injection, Placebo
Drug
Lead sponsor
Reunion Neuroscience Inc
Industry
Eligibility
18 Years to 74 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
28
States / cities
Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 1 Interventional

AP-011 Study to Evaluate the Safety of a Single Intra-articular Injection of Ampion™ for Arthritis of the Basal Thumb Joint

NCT02762760
View directory record Official record
Conditions
Osteoarthritis of the Hand
Interventions
AMPION™, Saline
Biological
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 2 Interventional

Use of Ketamine Prior to Cardiopulmonary Bypass in Children

NCT00556361
View directory record Official record
Conditions
Ventricular Septal Defect
Interventions
saline, ketamine
Drug
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
Up to 1 Year
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2007 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults

NCT02810340
View directory record Official record
Conditions
Meningococcal Vaccines
Interventions
Adjuvanted MCV-5, Non-Adjuvanted MCV-5, Menactra®
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Immunomodulatory Properties of Ketamine in Sepsis

NCT01089361
View directory record Official record
Conditions
Sepsis
Interventions
Ketamine, Normal Saline placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
21 Years to 100 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Sex Differences in Risk for Alcohol Abuse

NCT04543942
View directory record Official record
Conditions
Alcohol Abuse
Interventions
Alcohol, Saline
Drug
Lead sponsor
Mark Fillmore
Other
Eligibility
21 Years to 29 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults

NCT07059182
View directory record Official record
Conditions
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE, Prevention of Pneumococcal-induced Acute Otitis Media
Interventions
Inactivated whole-cell Streptococcus pneumoniae vaccine, Placebo
Biological · Drug
Lead sponsor
Serum Life Science Europe GmbH
Industry
Eligibility
18 Years to 49 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 2 Interventional Results available

Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 120 Days (SL120)

NCT01595646
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Saline, Insulin detemir, Insulin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 89 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease

NCT03070782
View directory record Official record
Conditions
Elevated Lipoprotein(a), Cardiovascular Disease
Interventions
ISIS 681257, Placebo
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Cottonwood, Arizona • Huntington Beach, California • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.

NCT04589403
View directory record Official record
Conditions
Healthy
Interventions
OPT101
Drug
Lead sponsor
Op-T LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Centennial, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 17, 2026, 9:04 AM EDT
Completed Phase 2 Interventional

Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine

NCT02114060
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
GEN-003 Vaccine (30μg of each antigen), GEN-003 Vaccine (60μg of each antigen), Matrix-M2 Adjuvant (25μg), Matrix-M2 Adjuvant (50μg), Matrix-M2 Adjuvant (75μg), Placebo
Biological
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
16
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 17, 2026, 9:04 AM EDT